Mutant RXRA protein results in increased binding to the peroxisome proliferator activator receptors (PPARs) and hyperactivation of PPAR target genes that support tumor growth, raising the potential for therapeutic intervention targeting the PPARG:RXRA heterodimer [79]. The gene discussed is RXRA; the disease is neoplasm.